Pharmaceuticals, Biotechnology and Life Sciences
— First-in-human trial will test the safety, pharmacokinetics and preliminary efficacy of microRNA therapeutic candidate INT-1B3 — UTRECHT, The Netherlands–(BUSINESS…
HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together…
Clovis reported a net loss for the first quarter of 2020 of $99.3 million, or ($1.39) per share, compared to the net loss for the first quarter of 2019 which was $86.4 million, or ($1.63) per share. Net loss for the first quarter of 2020 included share-based compensation expense of $13.0 million, compared to $13.6 million for the first quarter of 2019.
Deciphera Pharmaceuticals has ended the first quarter 2020 with cash, cash equivalents and marketable securities of $691.5 Million, with cash runway expected into the second half of 2022, and posts net loss of $72.8 million.
Lineage has applied for grant funding from the California Institute for Regenerative Medicine (CIRM) to support the use of VAC, Lineage’s allogeneic dendritic cell therapy, toward the development of a potential vaccine against SARS-CoV-2, the virus which causes COVID-19.
CANTON, Mich. & SHANGHAI–(BUSINESS WIRE)–#Alzheimers–MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – announced that a successful collaboration with…
Total product and royalty revenues of $569 million (+24% vs Q1 2019) for the quarter ended March 31, 2020; Jakafi® (ruxolitinib) revenues of $459 million in Q1 2020 (+22% vs Q1 2019).
– Monotherapy Phase I dose escalation remains ongoing; BT5528 appears well-tolerated as dosing approaches clinically relevant levels – BT5528 is…
First participants have been dosed at NYU Grossman School of Medicine and University of Maryland School of Medicine.
Athersys started enrollment of patients testing MultiStem cell therapy in a rapid advancement of clinical program for the treatment of ARDS based on prior clinical data reflecting favorable tolerability data and meaningful benefits on mortality, ventilator-free days and ICU-days